HIV-DNA: nuovo marcatore virologico. Metodiche a confronto per la quantificazione di HIV-DNA

Size: px
Start display at page:

Download "HIV-DNA: nuovo marcatore virologico. Metodiche a confronto per la quantificazione di HIV-DNA"

Transcription

1 HIV-DNA: nuovo marcatore virologico Metodiche a confronto per la quantificazione di HIV-DNA Maria Carla Re Laboratorio Retrovirus e Agenti infettivi HIV correlati UO di Microbiologia, Università di Bologna Alma Mater Studiorum

2 HIV DNA: a new must for HIV patients In latently infected cells the proviral DNA, integrated in the host s genome, does not actively replicate becomes invisible to the host immune system is unaffected by existing antiviral drugs is responsible of viral rebound The HIV-1 reservoir is highly complex memory CD4+ T cells are the most infected cells and different T-cell subsets macrophages,microglial cells, lymphoid organs and gastrointestinal tract have been found to harbor latent infection

3 HIV DNA predictor of the outcome of HIV-1 infection Early treatments lead to low levels of HIV-1 DNA It is a potential indicator for the initiation of antiretrovirals High levels were associated to rapid progression to AIDS and death. Association was independent of HIV- 1 RNA levels and CD4 counts A low DNA load (<10 copies/ml ) is a strong marker to exclude HIV-1 associated nephropathy and HIV-1 neurocognitive disorders Riva et al., 2003; Goujard C et al. 2006; Nicastri E et al., 2008, Coiras et al 2009; Masquelier et al., 2011; Sarmati et al 2012; Lambert-Niclot et al 2012, Demetriou et 2012; Tsiara et al

4 The perfect HIV-1 DNA quantification assay offer higher sensitivity and specificity should also be cost-effective technically easy to implement in clinical laboratories Proviral HIV-1 DNA is detectable in three major forms that reflect the different stages and fates of development during viral replication: the linear nonintegrated form the circular nonintegrated form found exclusively in the nucleus as 1-LTR and 2-LTR based on the number of LTR in HIV-1 DNA. half-life: short or long the linear integrated provirus. linear DNA: also called provirus Stable enough during the infection course Nucleus Transcribed or latent state

5 Nonintegrated HIV-1 DNA linear the most abundant form It is the direct product of reverse transcribed viral RNA and is the substrate for the integration reaction. Nonintegrated HIV-1 DNA circular 1-LTR circles 2-LTR circles Besides integrated DNA or proviral DNA, various forms of unintegrated cdna exist in the infected cell The relative proportion of integrated to unintegrated forms can vary from 1:1 to 1:100 in vitro considered to be the dead end products of abortive infections Indicative of recent viral infection (2-LTR circles: on the basis of the notion that these circles are unstable) Predictor of disease progression and decreased response to antiretroviral therapy.

6 Integrated HIV-1 DNA (provirus) and non integrated DNA Which is the right choice? Total HIV-1 DNA (integrated and non integrated forms) Integrated HIV -1 DNA (provirus) Long half life Long half life Short half-life Unintegrated HIV-1 DNA It is not always a suitable estimate of proviral DNA (in treated patients) monitoring of therapeutic approaches Is significantly lower in elite suppressors than that found in HAART treated patients Is a better indicator of reservoir size. Treated patients often have excess of unintegrated forms 2-LTR circles might be a marker of nascent infections (?) 2-LTR increase circle levels during drug intensification are indicative of ongoing viral replication 2-LTR circles are exclusively found in the nucleus, they have become a useful marker of viral nuclear import in studies of viral trafficking

7 Total HIV-1 DNA Real-time PCR has been the most common for quantification of total (integrated and nonintegrated HIV-1 DNA) by in-house protocols 1. by using many targets including pol gene, gag gene or gag-pol junction and also the conserved region of the long terminal repeat (LTR) [more sensitive, specific and reproducible than pol or gag based Assays] 2. by PCR optimized with 2 sets of primers targeting LTR and gag 3. by methods based on primers that amplify the viral sequence between the 5 LTR region and the gag gene The sensitivity of these different in-house techniques is expressed in various ways, making comparisons difficult between studies. The measure of total HIV-1 DNA should then approach the level of integrated HIV-1 DNA in patients on HAART since unintegrated HIV-1 DNA has a short half-life

8 Total HIV-1 DNA: a couple of examples Correlations of pre-art HIV-DNA with outcome in first-line treated ART patients Total HIV-DNA: modified version of a commercial Kit (Surdo et al 2015) Results, normalized by CD4 +, show that: Pre-ART HIV-DNA content in CD4+ cells strongly correlated with baseline viroimmunologic parameters and inflammation markers. Baseline HIV-DNA was also found to predict virological rebound in a cohort of 1st-line ART. 3 real-time PCR protocols (pol real-time PCR, gag real-time PCR, LTR real-time PCR ) LTR real-time PCR: higher correlation between PBMCs HIV-1 DNA and viremia The presence of mismatches between primers, probes and patients sequences is the most frequent and reasonable reason for under-evaluation or lack of detection (primers and probes are located in genomic regions non-conserved or involved in drug resistance) Ceccherini-Silberstein et al., ICONA at CROI 2016 Rozera et al. JVM 2010

9 Author Sample Target Detection method Control gene Estimated LOQ Desiré 2001 PBMCs pol Taqman probe Albumine 10 cp/10 6 PMBC Ericksson 2003 CD4 pol Taqman probe Albumine 2 cp/10 4 CD4+ Gibellini 2004 PBMCs pol SYBR green Globin 5 cp/ PBMCs Zhao 2002 PBMCs gag Taqman probe Internal QS 10 cp/10 6 PBMCs Lillo 2004 PBMCs commercial Taqman probe DNA QS DNA-QS 1.7 log 10 cp/106 PBMCs Gibellini 2008 PBMCs gag SYBR green Globin 5cp/PCR reaction Kabamba 2005 CD4 Gag /pol Taqman probe Globin 5cp/PCR reaction Pasternak 2008 PBMCs gag Taqman probe Beta-actin 4 cp/pcr reaction Avettand Fenoel 2009 PBMCs /W.B LTR Molecular beacons none 40 cp/10 6 PBMCs Beloukas 2009 PBMCs LTR /gag Molecular beacons CCR5 gene 12.5 copies/10 6 PBMCs Kostrikis 2002 PBMCs From 5 LTR to gag Taqman probe CCR5 gene 10 copies/106 6 PBMCs Casabianca 2007 W.blood From 5 LTR to gag SYBR green none 2 cp/mg of DNA Modified from E.K. Alidjinou et al., 2015

10 Integrated HIV-1 DNA Several PCR assays such as inverse PCR, linker ligation PCR (not strictly quantitative) More sensitive alternative (Alu-gag PCR) combined a pre-amplification step (performed with primers that bind genomic Alu elements and HIV-1 gag sequences) and a nested real-time PCR that quantities HIV-1 LTR sequences using molecular beacon detection The sensitivity of this method was increased by incorporating a repetitive sampling technique to detect rare integration events that occur near an Alu repeat.

11 HIV nonintegrated DNA HIV-1 LTR Amplification of 1-LTR circles is complicated by the inherent homology of the LTR sequence present in all cdna forms Primers designed for 1-LTR circle detection were able to amplify spurious products from other cdna forms including linear cdna molecules and integrated provirus HIV nonintegrated DNA HIV-2 LTR The 2-LTR circles have been readily quantified by PCR assays, due to its unique LTR- LTR junction Stable or not? It has been argued that 2-LTR circles are quickly degraded in HIV -infected cells However the presence of 2-LTR circles to be used as a marker for ongoing de novo infection in patients. By the use of fluorescence-monitored PCR (Taqman) to quantitate the metabolism of HIV cdna early after infection. Contrary to previous work, it was found that 2-LTR circles are actually quite stable (Butler et al.2002)

12 HIV nonintegrated DNA HIV-2 LTR Total HIV-1 DNA, unspliced (us) and multiply spliced HIV-1 RNA, and 2LTR circles can be quantified by digital PCR in peripheral blood Digital PCR is an alternative to real-time PCR in which each sample is divided into thousands of independent microscopic reactions prior to PCR amplification Kiselinova et al., PLoS Pathog. 2016

13 An unsolved question: HIV detected by PCR is a competent or a defective virus? Pt PBMC Limiting dilution culture PHA activation and g irradiated PBMC 1 2 Resting CD4 cells PBMC are collected from HIV-1 infected individuals and resting CD4 + T cells (CD25, CD69, HLA-DR ) are purified. Resting T cells are plated in 5-fold serial dilutions in duplicate from 1,000,000 to 320 cells per well. To reverse latency HIV-1 provirus, patient cells are activated with PHA and a 10-fold excess of irradiated PBMC from healthy donors Laird et al. Plos Pathog 2013 Target cells for HIV-1 infection are added to allow outgrowth of replication-competent HIV-1 released from infected cells in which latency has been reversed. In the MOLT-4/CCR5 viral outgrowth assay, MOLT-4/CCR5 cells are added on day 2 only. Day 2 Day 7 standard assay, HIV-1 p24 antigen ELISA is used to identify wells positive for HIV-1 outgrowth at 14 days. For the MOLT-4/CCR5 assay, RT-PCR is used to identify wells positive for outgrowth at 7 days.

14 Another possibility: the Tilda assay (Tat/rev Induced Limiting Dilution Assay) A novel assay to measure the magnitude of the inducible viral reservoir in HIV-infected individuals. To measure the frequency of cells with inducible multiply-spliced HIV RNA, as these transcripts are usually absent in latently infected cells but induced upon viral reactivation. TILDA requires less than a million cells, does not require RNA extraction and can be completed in two days. PBMCs isolation CD4 + T cells isolation. CD4 + T cells counted and plated (a 96 well plate) or stimulated for 12 h with PMA/ionomycin. Tat/rev msrna were quantified by an ultrasensitive nested RT-PCR and the frequency of cells with inducible msrna was determined Procopio et al Biomedicine 2015

15 Is it possible to predict HIV-1 eradication in latent reservoir? A 2,000-fold reductions are required to permit a majority of patients to interrupt ART for 1 y without rebound and that rebound may occur suddenly after multiple years. Greater than 10,000-fold reductions may be required to prevent rebound altogether. Alison L. Hilla et al. PNAS 2014 The stochastic viral decision. Each viral infection is a roll of the dice, with some probability of entering latency whatever the cellular activation state. Weinberger and Weinberger, Cell 2013

16 Four future statements To create a national network to obtain a well standardized method for HIV DNA detection, with high sensitivity and reproducibility (establishing a cut-off Total, integrated and nonintegrated DNA) To introduce, in the next guidelines, the suggestion (or the priority) for a quantitative test for HIV DNA detection (and to establish which forms) before therapy and during patients follow-up To study the presence of competent and/or defective HIV in reservoir Don t forget HIV DNA test in babies from HIV infected mothers Thanks to I. Bon, G. Musumeci, A. Bertoldi, S. Longo, G. Gallinella and D. Gibellini

Alexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout

Alexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4 + T-cell count at 96 weeks ART Alexander O.

More information

The relation between HIV- 1 integration and latency

The relation between HIV- 1 integration and latency The relation between HIV- 1 integration and latency Linos Vandekerckhove HIV translational research, Ghent Department of General Internal Medicine, Infectious Diseases and Psychosomatic Medicine University

More information

Droplet Digital PCR, the new tool in HIV reservoir quantification? Ward De Spiegelaere

Droplet Digital PCR, the new tool in HIV reservoir quantification? Ward De Spiegelaere Droplet Digital PCR, the new tool in HIV reservoir quantification? Ward De Spiegelaere Droplet Digital PCR, the new tool in HIV reservoir quantification? Content: - Digital PCR - Applications - Total HIV

More information

Towards a block and lock strategy: LEDGINs hamper the establishment of a reactivation competent HIV reservoir.

Towards a block and lock strategy: LEDGINs hamper the establishment of a reactivation competent HIV reservoir. Abstract no. MOLBPEA13 Towards a block and lock strategy: LEDGINs hamper the establishment of a reactivation competent HIV reservoir. G. Vansant,,A. Bruggemans, L. Vranckx, S. Saleh, I. Zurnic, F. Christ,

More information

Supplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR

Supplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR Supplemental Materials and Methods Plasmids and viruses To generate pseudotyped viruses, the previously described recombinant plasmids pnl4-3-δnef-gfp or pnl4-3-δ6-drgfp and a vector expressing HIV-1 X4

More information

Measuring the latent reservoir in vivo

Measuring the latent reservoir in vivo Series Editor: Robert F. Siliciano Measuring the latent reservoir in vivo Marta Massanella 1 and Douglas D. Richman 1,2 1 UCSD, La Jolla, California, USA. 2 VA San Diego Healthcare System, La Jolla, California,

More information

Supplementary Figure 1

Supplementary Figure 1 Supplementary Figure 1 Supplementary Figure 1: Cryopreservation alters CD62L expression by CD4 T cells. Freshly isolated (left) or cryopreserved PBMCs (right) were stained with the mix of antibodies described

More information

What do we measure when we measure cell associated HIV RNA

What do we measure when we measure cell associated HIV RNA https://doi.org/10.1186/s12977-018-0397-2 Retrovirology REVIEW Open Access What do we measure when we measure cell associated HIV RNA Alexander O. Pasternak * and Ben Berkhout Abstract Cell-associated

More information

Molecular Diagnosis Future Directions

Molecular Diagnosis Future Directions Molecular Diagnosis Future Directions Philip Cunningham NSW State Reference Laboratory for HIV/AIDS & Molecular Diagnostic Medicine Laboratory, SydPath St Vincent s Hospital Sydney Update on Molecular

More information

Clinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX

Clinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX Clinical Development of ABX464, drug candidate for HIV Functional Cure Jean-Marc Steens, MD Chief Medical Officer ABIVAX 1 DECLARATION OF CONFLICT OF INTEREST GSK ABIVAX 2 ABX464: Mechanism of Action ABX464

More information

Cell-associated HIV RNA: a dynamic biomarker of viral persistence

Cell-associated HIV RNA: a dynamic biomarker of viral persistence Pasternak et al. Retrovirology 2013, 10:41 REVIEW Open Access Cell-associated HIV RNA: a dynamic biomarker of viral persistence Alexander O Pasternak *, Vladimir V Lukashov and Ben Berkhout Abstract In

More information

Pathogenesis Update Robert F. Siliciano, MD, PhD

Pathogenesis Update Robert F. Siliciano, MD, PhD Pathogenesis Update Robert F. Siliciano, MD, PhD Professor of Medicine and Molecular Biology and Genetics Johns Hopkins University School of Medicine Investigator, Howard Hughes Medical Institute HIV-1

More information

Towards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco

Towards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco Towards an HIV Cure Steven G. Deeks Professor of Medicine University of California, San Francisco Why are we now talking about a cure? Emerging recognition that HAART does not fully restore health and/or

More information

Professor Jonathan Weber

Professor Jonathan Weber HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust Multidisciplinary Event to mark World AIDS Day 2011 British HIV Association (BHIVA) 2011 HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust

More information

With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the

With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several

More information

Trends in molecular diagnostics

Trends in molecular diagnostics Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling

More information

Identification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood

Identification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Identification and Characterization of CD4 T cells actively transcribing

More information

NIH Public Access Author Manuscript Curr Opin HIV AIDS. Author manuscript; available in PMC 2013 September 05.

NIH Public Access Author Manuscript Curr Opin HIV AIDS. Author manuscript; available in PMC 2013 September 05. NIH Public Access Author Manuscript Published in final edited form as: Curr Opin HIV AIDS. 2013 May ; 8(3): 170 175. doi:10.1097/coh.0b013e32835fc619. How to best measure HIV reservoirs? Christine Rouzioux

More information

HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial

HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3, Nicola Robinson 1,2,3, Sarah Fidler 4, Jonathan

More information

Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay

Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Background ImQuest BioSciences has developed and qualified a single-plate method to expedite the screening of antiviral agents against

More information

Beyond the replication competent HIV reservoir: transcription and translation competent reservoirs

Beyond the replication competent HIV reservoir: transcription and translation competent reservoirs https://doi.org/10.1186/s12977-018-0392-7 Retrovirology REVIEW Open Access Beyond the replication competent HIV reservoir: transcription and translation competent reservoirs Amy E. Baxter 1,2, Una O Doherty

More information

The HIV life cycle. integration. virus production. entry. transcription. reverse transcription. nuclear import

The HIV life cycle. integration. virus production. entry. transcription. reverse transcription. nuclear import The HIV life cycle entry reverse transcription transcription integration virus production nuclear import Hazuda 2012 Integration Insertion of the viral DNA into host chromosomal DNA, essential step in

More information

Module R: Recording the HIV Reservoir

Module R: Recording the HIV Reservoir Module R: Recording the HIV Reservoir Satish K. Pillai, Ph.D. MODULE LEADER Satish Pillai amfar Institute for HIV Cure Research Module R Team Michael Busch Timothy Henrich Sheila Keating Sulggi Lee Henry

More information

Inhibition of HIV-1 Integration in Ex Vivo-Infected CD4 T Cells from Elite Controllers

Inhibition of HIV-1 Integration in Ex Vivo-Infected CD4 T Cells from Elite Controllers JOURNAL OF VIROLOGY, Sept. 2011, p. 9646 9650 Vol. 85, No. 18 0022-538X/11/$12.00 doi:10.1128/jvi.05327-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Inhibition of HIV-1 Integration

More information

Innovative diagnostics for HIV, HBV and HCV

Innovative diagnostics for HIV, HBV and HCV Innovative diagnostics for HIV, HBV and HCV Dan Otelea National Institute for Infectious Diseases Bucharest, Romania Disclaimer No conflicts of interest Innovative diagnostics for HIV, HBV and HCV - is

More information

It takes more than just a single target

It takes more than just a single target It takes more than just a single target As the challenges you face evolve... HIV mutates No HIV-1 mutation can be considered to be neutral 1 Growing evidence indicates all HIV subtypes may be prone to

More information

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons

More information

Introduction retroposon

Introduction retroposon 17.1 - Introduction A retrovirus is an RNA virus able to convert its sequence into DNA by reverse transcription A retroposon (retrotransposon) is a transposon that mobilizes via an RNA form; the DNA element

More information

IAS 2015 Towards an HIV Cure symposium Vancouver. Distinct HIV Genetic Populations in Effector Memory T Cells after Prolonged Therapy

IAS 2015 Towards an HIV Cure symposium Vancouver. Distinct HIV Genetic Populations in Effector Memory T Cells after Prolonged Therapy IAS 25 Towards an HIV Cure symposium Vancouver Distinct HIV Genetic Populations in Effector Memory T Cells after Prolonged Therapy Questions about long-lived HIV reservoirs Effective ART Memory CD4+ T

More information

cure research HIV & AIDS

cure research HIV & AIDS Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may

More information

Immunodeficiency. (2 of 2)

Immunodeficiency. (2 of 2) Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related

More information

Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies

Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies Susanne Eriksson 1., Erin H. Graf 2., Viktor Dahl 1., Matthew C. Strain 3., Steven A. Yukl 4,5., Elena S. Lysenko 2, Ronald

More information

Supplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.

Supplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets. Supplementary information HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Chomont, N., M. El Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab,

More information

Beyond HAART: Outline. HIV-1 Time Line. Outline. Approaches to HIV Eradication 8/15/2013

Beyond HAART: Outline. HIV-1 Time Line. Outline. Approaches to HIV Eradication 8/15/2013 8/5/203 Beyond HAART: Approaches to HIV Eradication I have no financial conflicts of interest to disclose 8 August 203 Adam Spivak MD Visiting Instructor, Division of Infectious Diseases University of

More information

Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure

Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure Deborah Persaud, M.D. Associate Professor Department of Pediatrics Division of Infectious Diseases Johns Hopkins University School of

More information

Reservoir BINGO. Methods Small group work/ large group discussion

Reservoir BINGO. Methods Small group work/ large group discussion Reservoir BINGO Objectives Describe the differences in current technologies available for measuring the reservoir Discuss the risk and benefit of each technology Methods Small group work/ large group discussion

More information

HIV-1 Dual Infection and Neurocognitive Impairment

HIV-1 Dual Infection and Neurocognitive Impairment HIV-1 Dual Infection and Neurocognitive Impairment Gabriel Wagner, MD Assistant Professor of Medicine Infectious Diseases & Global Public Health UC San Diego HIV-Associated End Organ Damage Antiretroviral

More information

Complicated viral infections

Complicated viral infections Complicated viral infections Clinical case discussion Diagnostic dilemmas NSW State Reference Laboratory for HIV St Vincent s Hospital Sydney Diagnostic dilemmas Indeterminate or discordant serology (western

More information

The HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK

The HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK The HIV Cure Agenda CHIVA Oct 2016 Nigel Klein Institute of Child Health and Great Ormond Street Hospital, London, UK 2 How frequently is HIV cured? The Berlin patient Restriction of HIV entry CD4 is

More information

Complete Transcriptome Analysis of Latently Infected CD4 + T Cells

Complete Transcriptome Analysis of Latently Infected CD4 + T Cells Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Complete Transcriptome Analysis of Latently Infected CD4 + T Cells Fabio Romerio Institute of Human Virology University of Maryland School

More information

Invited Review CROI 2018: Advances in Basic Science Understanding of HIV

Invited Review CROI 2018: Advances in Basic Science Understanding of HIV Invited Review CROI 2018: Advances in Basic Science Understanding of HIV Mario Stevenson, PhD The conference on Retroviruses and Opportunistic Infections represents the most important venue for the dissemination

More information

HIV Cure Update. Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS

HIV Cure Update. Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS HIV Cure Update Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS Financial Disclosures Research grants paid to my institution: Gilead Sciences, Bristol

More information

Low-Level Viremia in HIV

Low-Level Viremia in HIV Mountain West AIDS Education and Training Center Low-Level Viremia in HIV Brian R. Wood, MD Medical Director, Mountain West AETC ECHO Telehealth Program Assistant Professor of Medicine, University of Washington

More information

HIV-1 Eradication: Early Trials (and Tribulations)

HIV-1 Eradication: Early Trials (and Tribulations) Feature Review HIV-1 Eradication: Early Trials (and Tribulations) Adam M. Spivak 1 and Vicente Planelles 2, * Antiretroviral therapy (ART) has rendered HIV-1 infection a manageable illness for those with

More information

Human Immunodeficiency Virus

Human Immunodeficiency Virus Human Immunodeficiency Virus Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Viruses and hosts Lentivirus from Latin lentis (slow), for slow progression of disease

More information

HIV & AIDS: Overview

HIV & AIDS: Overview HIV & AIDS: Overview UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL SEMINAR VJ TEMPLE 1 What

More information

Update on HIV Cure Research

Update on HIV Cure Research Update on HIV Cure Research Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland FORMATTED: /7/5 New Orleans, Louisiana: December 5-7,

More information

, virus identified as the causative agent and ELISA test produced which showed the extent of the epidemic

, virus identified as the causative agent and ELISA test produced which showed the extent of the epidemic 1 Two attributes make AIDS unique among infectious diseases: it is uniformly fatal, and most of its devastating symptoms are not due to the causative agent Male to Male sex is the highest risk group in

More information

HIV 101: Fundamentals of HIV Infection

HIV 101: Fundamentals of HIV Infection HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able

More information

NIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2013 September 01.

NIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2013 September 01. NIH Public Access Author Manuscript Published in final edited form as: J Acquir Immune Defic Syndr. 2012 September 1; 61(1): 19 22. doi:10.1097/qai.0b013e318264460f. Evaluation of HIV-1 Ambiguous Nucleotide

More information

Fayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES

Fayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES 1 of 7 I. Viral Origin. A. Retrovirus - animal lentiviruses. HIV - BASIC PROPERTIES 1. HIV is a member of the Retrovirus family and more specifically it is a member of the Lentivirus genus of this family.

More information

Clinical use of HIV-DNA quantity and resistance testing

Clinical use of HIV-DNA quantity and resistance testing Clinical use of HIV-DNA quantity and resistance testing Personal fees and travel grants Abbott Molecular Gilead Sciences Janssen-Cilag Merck Sharp and Dohme ViiV Healthcare Research and educational grants

More information

LESSON 4.6 WORKBOOK. Designing an antiviral drug The challenge of HIV

LESSON 4.6 WORKBOOK. Designing an antiviral drug The challenge of HIV LESSON 4.6 WORKBOOK Designing an antiviral drug The challenge of HIV In the last two lessons we discussed the how the viral life cycle causes host cell damage. But is there anything we can do to prevent

More information

HIV INFECTION: An Overview

HIV INFECTION: An Overview HIV INFECTION: An Overview UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL MBBS II SEMINAR VJ

More information

Tools to Monitor HIV Infection in 2013 and Beyond.

Tools to Monitor HIV Infection in 2013 and Beyond. Tools to Monitor HIV Infection in 2013 and Beyond. Federico García, fegarcia@ugr.es Servicio de Microbiología Univ. Hospital San Cecilio Granada, Spain Outline Address clinical questions: Ultra sensitive

More information

HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients

HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients ORIGINAL ARTICLE VIROLOGY HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients M. C. Re 1,2, F. Vitone 1, C. Biagetti 3, P. Schiavone 1, F. Alessandrini 1, I. Bon 1, E. de Crignis

More information

CROI 2013: Basic Science Review

CROI 2013: Basic Science Review CROI 2013: Basic Science Review Mario Stevenson, PhD The 20th Conference on Retroviruses and Opportunistic Infections was held in Atlanta, Georgia, and featured strong coverage in several basic science

More information

Virological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo

Virological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline

More information

How HIV Causes Disease Prof. Bruce D. Walker

How HIV Causes Disease Prof. Bruce D. Walker How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of

More information

Pediatric HIV Cure Research

Pediatric HIV Cure Research Pediatric HIV Cure Research HIV Cure Research Training Curriculum Pediatric HIV Cure Research Presented by: Priyanka Uprety,MSPH, PhD Laboratory of Deborah Persaud, MD Johns Hopkins University July 2016

More information

Herpesviruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics

Herpesviruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics Herpesviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Virion Enveloped icosahedral capsid (T=16), diameter 125 nm Diameter of enveloped virion 200 nm Capsid

More information

Professor Anna Maria Geretti

Professor Anna Maria Geretti THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Anna Maria Geretti Institute of Infection & Global Health, University of Liverpool 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT

More information

Diversity and Tropism of HIV-1 Plasma Rebound Virus after Treatment Discontinuation

Diversity and Tropism of HIV-1 Plasma Rebound Virus after Treatment Discontinuation Diversity and Tropism of HIV-1 Plasma Rebound Virus after Treatment Discontinuation By: Blake M. Hauser Senior Honors Thesis Department of Biology College of Arts and Sciences The University of North Carolina

More information

Can we eradicate HIV?

Can we eradicate HIV? Can we eradicate HIV? New therapeutic strategies towards a cure Laurence COLIN Laboratory of Molecular Virology University of Brussels Belgium The success story of HAART encountered solid barriers to virus

More information

VIRAL TITER COUNTS. The best methods of measuring infectious lentiviral titer

VIRAL TITER COUNTS. The best methods of measuring infectious lentiviral titer VIRAL TITER COUNTS The best methods of measuring infectious lentiviral titer FLUORESCENCE CYCLES qpcr of Viral RNA SUMMARY Viral vectors are now routinely used for gene transduction in a wide variety of

More information

HIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg

HIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg HIV viral load testing in the era of ART Christian Noah Labor Lademannbogen, Hamburg 1 Life expectancy of patients on ART Data from the UK Collaborative HIV Cohort (UK CHIC) Requirements: Early diagnosis

More information

For in vitro Veterinary Diagnostics only. Kylt Rotavirus A. Real-Time RT-PCR Detection.

For in vitro Veterinary Diagnostics only. Kylt Rotavirus A. Real-Time RT-PCR Detection. For in vitro Veterinary Diagnostics only. Kylt Rotavirus A Real-Time RT-PCR Detection www.kylt.eu DIRECTION FOR USE Kylt Rotavirus A Real-Time RT-PCR Detection A. General Kylt Rotavirus A products are

More information

Clinical Importance of DNA and RNA determinants

Clinical Importance of DNA and RNA determinants Clinical Importance of DNA and RNA determinants Akin Abayomi MD Lady Meade Ref Unit Lab Barbados and Division of Haematopathology, University of Stellenbosch, Cape Town, South Africa. Abayomi@sun.ac.za

More information

Fig. 1: Schematic diagram of basic structure of HIV

Fig. 1: Schematic diagram of basic structure of HIV UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL SEMINAR HIV & AIDS: An Overview What is HIV?

More information

Diagnosis of HIV-1 Infection in Children Younger Than 18 Months in the United States

Diagnosis of HIV-1 Infection in Children Younger Than 18 Months in the United States TECHNICAL REPORT Diagnosis of HIV-1 Infection in Children Younger Than 18 Months in the United States Jennifer S. Read, MD, MS, MPH, DTM&H, and the Committee on Pediatric AIDS ABSTRACT The objectives of

More information

Laboratory for Clinical and Biological Studies, University of Miami Miller School of Medicine, Miami, FL, USA.

Laboratory for Clinical and Biological Studies, University of Miami Miller School of Medicine, Miami, FL, USA. 000000 00000 0000 000 00 0 bdna () 00000 0000 000 00 0 Nuclisens () 000 00 0 000000 00000 0000 000 00 0 Amplicor () Comparison of Amplicor HIV- monitor Test, NucliSens HIV- QT and bdna Versant HIV RNA

More information

Journal of Infectious Diseases Advance Access published July 11, Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers

Journal of Infectious Diseases Advance Access published July 11, Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers Journal of Infectious Diseases Advance Access published July 11, 2013 1 Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers Tae-Wook Chun 1,6, J. Shawn Justement 1, Danielle Murray

More information

HIV remission: viral suppression in the absence of ART. Sarah Fidler Brian Gazzard Lecture BHIVA 2016

HIV remission: viral suppression in the absence of ART. Sarah Fidler Brian Gazzard Lecture BHIVA 2016 HIV remission: viral suppression in the absence of ART Sarah Fidler Brian Gazzard Lecture BHIVA 2016 Disclosures: My institution receives funding for research from MSD, GSK, ViiV, Gilead Summary of talk

More information

MedChem 401~ Retroviridae. Retroviridae

MedChem 401~ Retroviridae. Retroviridae MedChem 401~ Retroviridae Retroviruses plus-sense RNA genome (!8-10 kb) protein capsid lipid envelop envelope glycoproteins reverse transcriptase enzyme integrase enzyme protease enzyme Retroviridae The

More information

I declare that I have no financial conflicts of interest

I declare that I have no financial conflicts of interest I declare that I have no financial conflicts of interest Cytotoxic T-Lymphocytes Eliminate Defective HIV Proviruses Without Impacting Infectious Reservoirs R. Brad Jones Assistant Professor The George

More information

T-Pharmacytes for the Targeted Eradication of HIV Reservoirs

T-Pharmacytes for the Targeted Eradication of HIV Reservoirs T-Pharmacytes for the Targeted Eradication of HIV Reservoirs Walker Lab Rachel O Connor Alicja Trocha Dan Karel Irvine Lab Stefanie Mueller Humanized Mouse Core Vlad Vrbanac Andy Tager Todd Allen Darrell

More information

Can HIV be cured? (how about long term Drug free remission?)

Can HIV be cured? (how about long term Drug free remission?) Can HIV be cured? (how about long term Drug free remission?) Shirin Heidari International AIDS Society EC Think Tank meeting 27-28 October 2010 Luxemburg HAART can control HIV, cannot eradicate it Life

More information

Bacteria and Viruses

Bacteria and Viruses CHAPTER 13 LESSON 3 Bacteria and Viruses What are viruses? Key Concepts What are viruses? How do viruses affect human health? What do you think? Read the two statements below and decide whether you agree

More information

PROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater

PROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater PROSPECTS FOR HIV CURE IN ADULTS FIS 2013 Nov 11 th 2013 John Frater April 29 th 2013; Telegraph online THE COMPONENTS OF A CURE. What is cure? Issues to consider: Post treatment control the benefit of

More information

HIV Basics: Pathogenesis

HIV Basics: Pathogenesis HIV Basics: Pathogenesis Michael Saag, MD, FIDSA University of Alabama, Birmingham Director, Center for AIDS Research ACTHIV 2011: A State-of-the-Science Conference for Frontline Health Professionals Learning

More information

Targeting latent HIV infection: on the road towards an HIV Cure

Targeting latent HIV infection: on the road towards an HIV Cure Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Targeting latent HIV infection: on the road towards an HIV Cure David M. Margolis, MD Professor of Medicine Treatment Cure Prevention Prevention

More information

HIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks

HIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks HIV Antibody Characterization for Reservoir and Eradication Studies Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks Blood Systems Research Institute University of California San Francisco, CA

More information

AIDS free generation. Bob Colebunders Institute of Tropical Medicine

AIDS free generation. Bob Colebunders Institute of Tropical Medicine AIDS free generation Bob Colebunders Institute of Tropical Medicine Why this optimism? Rapid scale-up of antiretroviral therapy Treatment can prevent new infections Expanded coverage of programmes to prevent

More information

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects Maria J Buzón 1,9, Marta Massanella 1,9, Josep M Llibre 2, Anna Esteve 3, Viktor Dahl 4, Maria

More information

Supporting Information

Supporting Information Supporting Information Palmisano et al. 10.1073/pnas.1202174109 Fig. S1. Expression of different transgenes, driven by either viral or human promoters, is up-regulated by amino acid starvation. (A) Quantification

More information

Infezione da HIV: Possibilità di eradicazione. Claudia Alteri

Infezione da HIV: Possibilità di eradicazione. Claudia Alteri Infezione da HIV: Possibilità di eradicazione Claudia Alteri Definitions Residual viremia: Persistent HIV-RNA measured in plasma at levels below the limit of detection of the standard clinical assay Viral

More information

ID Week 2016: HIV Update

ID Week 2016: HIV Update Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation

More information

WHO Prequalification of Diagnostics Programme PUBLIC REPORT. Product: VERSANT HIV-1 RNA 1.0 Assay (kpcr) Number: PQDx

WHO Prequalification of Diagnostics Programme PUBLIC REPORT. Product: VERSANT HIV-1 RNA 1.0 Assay (kpcr) Number: PQDx WHO Prequalification of Diagnostics Programme PUBLIC REPORT Product: VERSANT HIV-1 RNA 1.0 Assay (kpcr) Number: PQDx 0115-041-00 Abstract The VERSANT HIV-1 RNA 1.0 Assay (kpcr) with product codes 10375763,

More information

RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis

RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis 1 B R E N D A N M C M U L L A N I N F E C T I O U S D I S E A S E S, S Y D N E Y C H I L D R E N S H O S P I T A L S C H O O L O F W O

More information

Sysmex Educational Enhancement and Development No

Sysmex Educational Enhancement and Development No SEED Haematology No 1 2015 Introduction to the basics of CD4 and HIV Viral Load Testing The purpose of this newsletter is to provide an introduction to the basics of the specific laboratory tests that

More information

Diagnostic Methods of HBV and HDV infections

Diagnostic Methods of HBV and HDV infections Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection

More information

Development of 5 LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals

Development of 5 LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals Trejbalová et al. Clinical Epigenetics (2016) 8:19 DOI 10.1186/s13148-016-0185-6 RESEARCH Development of 5 LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals

More information

Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4 T Cell Model without Inducing Global T Cell Activation

Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4 T Cell Model without Inducing Global T Cell Activation JOURNAL OF VIROLOGY, June 2011, p. 6060 6064 Vol. 85, No. 12 0022-538X/11/$12.00 doi:10.1128/jvi.02033-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Disulfiram Reactivates

More information

Inves&gación básica y curación del VIH-1

Inves&gación básica y curación del VIH-1 Inves&gación básica y curación del VIH-1 Javier Mar&nez-Picado 24 th Conference on Retroviruses and Opportunis6c Infec6ons UNIVERSITAT DE VIC Empezamos bien cart: How Early is Early Enough? Sáez-Cirion

More information

Analysis of HIV-1 Resistance Mutations from various Compartments of the Peripheral Blood in Patients with Low-Level Viremia

Analysis of HIV-1 Resistance Mutations from various Compartments of the Peripheral Blood in Patients with Low-Level Viremia Andrea Freystetter / Christian Paar / Herbert Stekel / Jörg Berg Analysis of HIV-1 Resistance Mutations from various Compartments of the Peripheral Blood in Patients with Low-Level Viremia 107 - Translationale

More information

T Memory Stem Cells: A Long-term Reservoir for HIV-1

T Memory Stem Cells: A Long-term Reservoir for HIV-1 Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 T Memory Stem Cells: A Long-term Reservoir for HIV-1 Maria J Buzon, PhD Ragon Institute of MGH, MIT and Harvard, Massachussetts General Hospital,

More information

HIV transcription, Tat transactivation mrna processing and latency

HIV transcription, Tat transactivation mrna processing and latency HIV transcription, Tat transactivation mrna processing and latency Tat transactivation Roles of CTD kinases in HIV replication Latency and reservoir Strategies to eliminate the reservoir of HIV in the

More information

Nature Medicine: doi: /nm.2109

Nature Medicine: doi: /nm.2109 HIV 1 Infects Multipotent Progenitor Cells Causing Cell Death and Establishing Latent Cellular Reservoirs Christoph C. Carter, Adewunmi Onafuwa Nuga, Lucy A. M c Namara, James Riddell IV, Dale Bixby, Michael

More information

Panther has new prey

Panther has new prey Raising the Bar for Performance Testing Panther has new prey The Aptima HIV-1 Quant Dx assay leads the hunt for HIV-1 diagnosis and viral load monitoring. Freedom to work the way you choose Run what assays

More information

Early Antiretroviral Therapy

Early Antiretroviral Therapy Early Antiretroviral Therapy HIV Cure Research Training Curriculum HIV and Cure Early ART Presented by: Jintanat Ananworanich, MD, PhD June 2016 The HIV CURE research training curriculum is a collaborative

More information